Geneva Network
Research organisation working on international trade, innovation and health policy
Geneva Network is a public policy research and advocacy organisation working at the nexus of international intellectual property, health and trade issues.
28/11/2022
Seberapa penting sih hak kekayaan intelektual atau bagi Indonesia? Sudahkah kerangka kebijakan HAKI Indonesia mendukung? Apa dampak yang akan ditimbulkan oleh perubahan Undang-Undang Paten?
Mari diskusikan langsung bersama pakarnya di acara “Mendukung Pemulihan Ekonomi: Hak Kekayaan Intelektual dan Investasi Indonesia” kerja sama CIPS dan Geneva Network!
📆: Rabu, 30 November 2022
⏲️: 09.30-12.00 WIB
🖥: Hotel Bidakara, Jl. Gatot Subroto Kav. 71-73, Jakarta
Narasumber:
🎙Reni Yanita (Kementerian Perindustrian)
🎙Dr. Dra. Agusdini Banun Saptaningsih (Kementerian Kesehatan)
🎙Rani Nuradi S.Si (Kementerian Hukum dan HAM)
🎙Prof. Mark Schultz (University of Akron)
🎙Prof. Bryan Mercurio (Chinese University of Hong Kong)
Moderator: Ronald Tundang (CIPS)
📌 Daftar gratis di https://cutt.ly/BER-30Nov
26/04/2022
Our analysis of patenting on the WHO's latest Essential Medicine List (22nd edition, 2021) shows a decline in the percentage of patented medicines for the first time:
🌏 Only 35 out of the 477 total items (7.3%) on the EML are patented in a middle or low income country.
💡19% of lower income countries surveyed do not have any active patents listed for the 35 patented medicines on the 22nd EML.
🏃🏽♀️83% of lower income countries have 50 or fewer active EML medicine patents.
🇺🇳 Approximately 25% of all active EML patents in lower income countries are subject to an MPP license, bilateral license, and/or commitment to not enforce.
Congratulations to our Senior Fellow Mark Schultz for a great piece of analysis.
Read the study:
Essential Medicines and Patents on the World Health Organization Essential Medicines List 22nd Edition - Geneva Network Key Takeaways The latest edition of the World Health Organization’s Essential Medicines List, the 22nd Edition (2021), has seen a decline in the percentage of patented medicines for the first time since researchers have been tracking the number. As of January 2022, 35 out of the 477 total items (7...
15/03/2022
IP has been fundamental to R&D and manufacturing scale-up for the current pandemic, Philip Stevens and Mark Schultz write in this new Geneva Network paper.
For future pandemics, waiving or limiting IP would undermine R&D and manufacturing innovation, leaving the world reliant on unproven open source and IP-free models of vaccine development.
READ: https://lnkd.in/dRgbrzBk
The role of intellectual property rights in preparing for future pandemics - Geneva Network Even though IP has played a crucial role in developing and manufacturing vaccines for the current pandemic, some are calling for IP to be waived to facilitate preparations for future pandemics.